EA201890421A1 - Циклические соединения, пригодные в качестве модуляторов tnf-альфа - Google Patents

Циклические соединения, пригодные в качестве модуляторов tnf-альфа

Info

Publication number
EA201890421A1
EA201890421A1 EA201890421A EA201890421A EA201890421A1 EA 201890421 A1 EA201890421 A1 EA 201890421A1 EA 201890421 A EA201890421 A EA 201890421A EA 201890421 A EA201890421 A EA 201890421A EA 201890421 A1 EA201890421 A1 EA 201890421A1
Authority
EA
Eurasian Patent Office
Prior art keywords
tnf
connections suitable
alpha modulators
compounds
cyclic connections
Prior art date
Application number
EA201890421A
Other languages
English (en)
Inventor
Хай-Юнь Сяо
Мурали Т.Г. Дхар
Бинь Цзян
Цзиньву Дуань
Original Assignee
Бристол-Маерс Сквибб Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Бристол-Маерс Сквибб Компани filed Critical Бристол-Маерс Сквибб Компани
Publication of EA201890421A1 publication Critical patent/EA201890421A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Описаны соединение формулы (I)или их соли, где кольцо A представляет собой 3-6-членное карбоциклическое или гетероциклическое кольцо; X представляет собой CRили N; Y представляет собой -(CRR)-; Z представляет собой -(CRR)-; и q, R, R, R, R, R, R, R, Rи Rопределены в настоящем документе. Также описаны способы применения таких соединений в качестве модуляторов TNFα и фармацевтические композиции, содержащие такие соединения. Эти соединения являются полезными в лечении воспалительных и аутоиммунных заболеваний.
EA201890421A 2015-08-03 2016-08-02 Циклические соединения, пригодные в качестве модуляторов tnf-альфа EA201890421A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562200415P 2015-08-03 2015-08-03
PCT/US2016/045104 WO2017023902A1 (en) 2015-08-03 2016-08-02 Cyclic compounds useful as modulators of tnf alpha

Publications (1)

Publication Number Publication Date
EA201890421A1 true EA201890421A1 (ru) 2018-07-31

Family

ID=56610045

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201890421A EA201890421A1 (ru) 2015-08-03 2016-08-02 Циклические соединения, пригодные в качестве модуляторов tnf-альфа

Country Status (13)

Country Link
US (1) US10335392B2 (ru)
EP (1) EP3331889B1 (ru)
JP (1) JP6811233B2 (ru)
KR (1) KR20180031773A (ru)
CN (1) CN108137609B (ru)
AU (1) AU2016301215A1 (ru)
BR (1) BR112018001980A2 (ru)
CA (1) CA2994703A1 (ru)
EA (1) EA201890421A1 (ru)
ES (1) ES2828696T3 (ru)
IL (1) IL257159A (ru)
MX (1) MX2018001173A (ru)
WO (1) WO2017023902A1 (ru)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016168641A1 (en) 2015-04-17 2016-10-20 Abbvie Inc. Tricyclic modulators of tnf signaling
TW201702247A (zh) 2015-04-17 2017-01-16 艾伯維有限公司 作為ｔｎｆ信號傳遞調節劑之吲唑酮
WO2016168633A1 (en) 2015-04-17 2016-10-20 Abbvie Inc. Indazolones as modulators of tnf signaling
GB201510758D0 (en) 2015-06-18 2015-08-05 Ucb Biopharma Sprl Novel TNFa structure for use in therapy
GB201621907D0 (en) 2016-12-21 2017-02-01 Ucb Biopharma Sprl And Sanofi Antibody epitope
CA3179702A1 (en) 2020-05-05 2021-11-11 Nuvalent, Inc. Heteroaromatic macrocyclic ether chemotherapeutic agents
MX2022013657A (es) 2020-05-05 2023-02-01 Nuvalent Inc Quimioterápicos de éter macrocíclico heteroaromático.

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5149386A (ja) * 1974-10-28 1976-04-28 Hitachi Ltd Shuchukanshiseigyohoho
WO1998037072A1 (en) 1997-02-25 1998-08-27 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Substituted benzimidazoles as non-nucleoside inhibitors of reverse transcriptase
JPH11228539A (ja) * 1997-12-03 1999-08-24 Taisho Pharmaceut Co Ltd 含窒素四環性化合物
US7601846B2 (en) 2001-06-26 2009-10-13 The Regents Of The University Of California Compounds having activity as inhibitors of apoptosis
WO2003064422A1 (fr) 2002-01-31 2003-08-07 Daiichi Pharmaceutical Co., Ltd. Derive imidazo[1,2-a]pyridine
WO2004050035A2 (en) 2002-12-03 2004-06-17 Isis Pharmaceuticals, Inc. Benzimidazoles and analogs thereof as antivirals
US20050124638A1 (en) 2003-12-08 2005-06-09 Swayze Eric E. Benzimidazoles and analogs thereof as antivirals
EP2209785A1 (en) 2007-10-05 2010-07-28 S*BIO Pte Ltd 2-morpholinylpurines as inhibitors of pi3k
JP2009227599A (ja) 2008-03-21 2009-10-08 Daiichi Sankyo Co Ltd イミダゾピリダジン誘導体
CN101717397B (zh) 2008-10-09 2012-11-28 中国科学院上海药物研究所 一类取代吡啶并[2',1':2,3]咪唑并[4,5-c]异喹啉酮类化合物及其合成方法和用途,以及包含该类化合物的药物组合物
EP2411057B1 (en) 2009-03-23 2020-05-06 Eli Lilly and Company Imaging agents for detecting neurological disorders
US8691187B2 (en) 2009-03-23 2014-04-08 Eli Lilly And Company Imaging agents for detecting neurological disorders
WO2012148550A1 (en) 2011-02-25 2012-11-01 Myrexis, Inc. Prodrugs of therapeutic compounds
EP2527344A1 (en) 2011-05-25 2012-11-28 Almirall, S.A. Pyridin-2(1H)-one derivatives useful as medicaments for the treatment of myeloproliferative disorders, transplant rejection, immune-mediated and inflammatory diseases
WO2014009295A1 (en) 2012-07-13 2014-01-16 Ucb Pharma S.A. Imidazopyridine derivatives as modulators of tnf activity
GB201212513D0 (en) 2012-07-13 2012-08-29 Ucb Pharma Sa Therapeutic agents
KR101669334B1 (ko) * 2013-09-30 2016-10-25 주식회사 엘지화학 헤테로환 화합물 및 이를 포함하는 유기 발광 소자
GB201321744D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321738D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic Agents
GB201321742D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321741D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321728D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321746D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
EP3080085B1 (en) 2013-12-09 2019-08-14 UCB Biopharma SPRL Fused bicyclic heteroaromatic derivatives as modulators of tnf activity
GB201321739D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
ES2809535T3 (es) 2013-12-09 2021-03-04 UCB Biopharma SRL Derivados de imidazopiridina como moduladores de la actividad de TNF
GB201321743D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321745D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321735D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic Agents
GB201321737D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic Agents
SI3204386T1 (sl) 2014-10-06 2021-08-31 Signal Pharmaceuticals, Llc Substituirane spojine aminopurina, njihove sestave in načini zdravljenja v povezavi z njimi
CA2980161A1 (en) 2015-03-18 2016-09-22 Bristol-Myers Squibb Company Heterocyclic compounds useful as inhibitors of tnf
EA032315B1 (ru) 2015-03-18 2019-05-31 Бристол-Маерс Сквибб Компани Замещенные трициклические гетероциклические соединения
EP3271361B1 (en) 2015-03-18 2020-04-22 Bristol-Myers Squibb Company Tricyclic heterocyclic compounds useful as inhibitors of tnf

Also Published As

Publication number Publication date
US10335392B2 (en) 2019-07-02
WO2017023902A1 (en) 2017-02-09
EP3331889B1 (en) 2020-09-23
KR20180031773A (ko) 2018-03-28
US20180221344A1 (en) 2018-08-09
BR112018001980A2 (pt) 2018-09-18
JP2018525377A (ja) 2018-09-06
JP6811233B2 (ja) 2021-01-13
MX2018001173A (es) 2018-04-24
CN108137609B (zh) 2021-07-16
ES2828696T3 (es) 2021-05-27
CA2994703A1 (en) 2017-02-09
EP3331889A1 (en) 2018-06-13
CN108137609A (zh) 2018-06-08
AU2016301215A1 (en) 2018-03-22
IL257159A (en) 2018-03-29

Similar Documents

Publication Publication Date Title
EA201890165A1 (ru) Гетероциклические соединения, применимые в качестве модуляторов tnf-альфа
EA201890421A1 (ru) Циклические соединения, пригодные в качестве модуляторов tnf-альфа
EA201992884A2 (ru) Арильные, гетероарильные и гетероциклические соединения для лечения заболеваний
EA202090486A2 (ru) Соединения для лечения спинальной мышечной атрофии
EA201891103A1 (ru) Композиции для лечения спинальной мышечной атрофии
MX2022005839A (es) Compuestos utiles como inhibidores de la proteina helios.
EA201992126A1 (ru) Ингибиторы jak, содержащие 4-членный гетероциклический амид
EA201791011A1 (ru) 3-ЗАМЕЩЕННЫЕ 5-АМИНО-6H-ТИАЗОЛО[4,5-d]ПИРИМИДИН-2,7-ДИОНОВЫЕ СОЕДИНЕНИЯ ДЛЯ ЛЕЧЕНИЯ И ПРОФИЛАКТИКИ ВИРУСНЫХ ИНФЕКЦИЙ
EA201592126A1 (ru) 6-мостиковые гетероарилдигидропиримидины для лечения и профилактики заражения вирусом гепатита b
EA201792034A1 (ru) Замещенные трициклические гетероциклические соединения
EA201792025A1 (ru) Трициклические гетероциклические соединения, применимые в качестве ингибиторов tnf
EA202091484A1 (ru) 4-азаиндольные соединения
EA201691085A1 (ru) Замещенные бензамиды и способы их применения
EA201691261A1 (ru) Новые дигидрохинолизиноны для лечения и профилактики инфекции, вызванной вирусом гепатита b
EA202091480A1 (ru) Аминоиндольные соединения, пригодные в качестве ингибиторов tlr
EA201792054A1 (ru) Гетероциклические соединения, применимые в качестве ингибиторов tnf
EA201692114A1 (ru) Замещенные дигидроизохинолиноновые соединения
EA202090688A1 (ru) Бис-амидные соединения, активирующие саркомер, и варианты их применения
AU2018253590A1 (en) Imidazopyridazine compounds
EA201590381A1 (ru) Замещенные пиразолы, используемые в качестве блокаторов кальциевых каналов n-типа
EA201690135A1 (ru) Трициклические соединения бензоксаборола и их применение
EA202091400A1 (ru) Производные пиррола в качестве ингибиторов асс
EA201690972A1 (ru) Конденсированные гетероциклические соединения в качестве модуляторов ионных каналов
EA202091477A1 (ru) Замещенные соединения простых индольных эфиров
EA201692358A1 (ru) Производные изоиндолина для применения в лечении вирусной инфекции